{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-261716","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2026-06-08T20:07:47+00:00","discovered_at":"2026-06-08T20:09:01.299865+00:00","generated_at":"2026-06-08T20:10:05.842325+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Climb Bio stockholders elect Cumbo and Williams; reject charter amendment; approve equity plan amendment","bullets":["Alexander (Bo) Cumbo elected to Board with 26,035,689 votes for; Douglas Williams with 24,505,866 votes for.","Ratification of PricewaterhouseCoopers as FY2026 auditor: 35,206,304 for, 63,633 against, 2,552 abstain.","Charter amendment for 'cause' removal of directors failed: 27,299,535 for, 130,187 against, 7,841,185 broker non-votes.","2021 Equity Incentive Plan amendment approved: 19,604,493 for, 7,810,582 against, 7,841,185 broker non-votes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-261716","json":"https://secwatch.observer/filing/0001193125-26-261716.json","markdown":"https://secwatch.observer/filing/0001193125-26-261716.md","text":"https://secwatch.observer/filing/0001193125-26-261716.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526261716/0001193125-26-261716-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526261716/d72849d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T20:10:05.842325+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"341a746f95e61dea0988dbd86c4f24f95a453628","claim":"Climb Bio, Inc. shareholders approved Ratification of the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026 at the 2026-12-31 meeting.","evidence_excerpt":"2. The stockholders of the Company ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of the stockholders’ vote with respect to such matter were as follows: Votes For Votes Against Abstentions 35,206,304 63,633 2,552","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526261716/0001193125-26-261716-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-12-31"}],"fact_type":"shareholder_vote"},{"claim_id":"62e581c673f6628676157d221a99e1def6e86446","claim":"Climb Bio, Inc. shareholders approved Election of Alexander (Bo) Cumbo and Douglas Williams, Ph.D. to the Board of Directors.","evidence_excerpt":"1. The stockholders of the Company elected Alexander (Bo) Cumbo and Douglas Williams, Ph.D., to the Company’s Board of Directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his respective successor has been duly elected and qualified. The results of the stockholders’ vote with respect to such matter were as follows: Votes For Votes Withheld Broker Non- Votes Alexander (Bo) Cumbo 26,035,689 1,395,615 7,841,185 Douglas Williams, Ph.D. 24,505,866 2,924,838 7,841,185","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526261716/0001193125-26-261716-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"a439ce1c039ea3c1adf17cc156d8487a254d0f0f","claim":"Climb Bio, Inc. shareholders approved Approval of the 2021 Plan Amendment.","evidence_excerpt":"4. The stockholders of the Company approved the 2021 Plan Amendment. The results of the stockholders’ vote with respect to such matter were as follows: Votes For Votes Against Abstentions Broker Non- Votes 19,604,493 7,810,582 16,229 7,841,185","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526261716/0001193125-26-261716-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"fb044df62cf6351fd5fe46e8ded78d988ada1e88","claim":"Climb Bio, Inc. shareholders rejected Amendment to the Amended and Restated Certificate of Incorporation relating to the removal of directors for cause.","evidence_excerpt":"3. The stockholders of the Company did not approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, relating to the removal of directors for “cause”. The results of the stockholders’ vote with respect to such matter were as follows: Votes For Votes Against Abstentions Broker Non- Votes 27,299,535 130,187 1,582 7,841,185","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526261716/0001193125-26-261716-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"failed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}